(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

Our Mission

To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.

The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989

The U.S. Weight Loss & Diet Control Market

March 2023       427 Pages      160 tables/charts       Price: $1,995

The $75 billion U.S. weight loss market grew nearly 15% last year from the depressed level of 2020.  Most segments of the market have recovered from the Covid-19 pandemic and recession. The big story of 2022 has been the soaring demand for new obesity drugs such as Wegovy and Saxenda, with more new drugs coming soon. The market may be entering a new era of medical approaches. Even Weight Watchers is now providing a medical plan.

The frozen diet entrees market and diet soft drinks have shown surprising strength, but the health clubs industry was devasted by the pandemic and emerges as a smaller sector. Supply chain disruptions affected the MLM market for meal replacements into 2021 and 2022, tamping down growth for Herbalife and Medifast. The ranks of commercial weight loss centers have been thinned out, and chains had to pivot to virtual client meetings and drop shipping of
products.

Do-it-yourself plans still abound as consumers use free diet & fitness apps. Many untapped niches still exist.  This is a completely revised and updated analysis of Marketdata’s best-selling biennial study about the U.S. weight loss market. This is the most comprehensive investigation of the U.S. weight loss market published by anyone worldwide.

Covered… dollar value & growth rates of all major weight loss market segments (early 1980s to 2022 and 2023 & 2027 forecasts), latest market trends and developments, status reports for: diet soft drinks, artificial sweeteners, health clubs, commercial diet center chains, multi-level marketing diet plans, retail meal replacements & weight loss supplements, medical programs (weight loss surgery, MDs, hospitals/clinic programs, Rx diet drugs, bariatricians, VLCD programs), low-cal frozen entrees, and the diet books & exercise DVDs market.

New for this edition:

  • Effects of the Pandemic on operations & revenues for all market segments, analysis of the recovery
  • How dieter behavior changed with the pandemic
  • The skyrocketing market for Rx obesity drugs and MD programs
  • 2022 market performance, 2023 & 2027 Forecasts
  • The most popular diets today
  • Ranking of the leading competitor companies
  • Outlook for the 2023 diet season
  • Why MLM is a major force in meal replacements sales, tough year in 2022
  • The franchising slowdown.

Also included: 34-year revenue analysis of the market through past recessions and fad diet cycles, comprehensive dieter demographics, weight loss center franchising, and extensive national/state commercial centers’ operating ratios. Rankings & revenues of top commercial chains, brand sales, and a Reference Directory. Contains 34 in-depth competitor profiles for: Weight Watchers, Jenny Craig, NutriSystem, Medifast, Herbalife, Noom, Slim-Fast, Atkins Nutritionals, HMR, Optifast, Robard, Lindora Clinics, Slimgenics, Ideal Protein, Profile by Sanford, BeachBody, Metabolic Research, Smart For Life, Medi-Weightloss, Centers for Medical Weight Loss, Nuviva, JumptStart MD, Dr. G’s, more.

Report also sold by individual chapters at lower price. $99 Overview available.

 

Latest News

Lindora Clinics Now Selling Franchises

Sept. 19, 2024 Lindora Clinics, a long-time competitor in the medical weight loss market,  has begun selling franchises. The firm has 31 sites, focused on the California market, but plans to expand nationally via franchising. Lindora franchisees’ gross revenue can vary, but the data provided in the brand’s 2024 FDD offers insight into potential earnings, including: Average Gross Revenue of Qualified Clinics (for the period from March 2023 to February 2024): Ranged from $71,268 to $93,056 per month. $855,000 –

Read More »

Noom Offers Compounded Weight Loss Drugs

Sept. 12, 2024 Noom is the latest weight loss company to start prescribing compounded versions of the obesity medication semaglutide. This follows similar moves by Hims, Ro, and other telehealth companies capitalizing on shortages of brand-name obesity drugs. Noom  will sell the compounded GLP-1 drug starting at $149 a month, it says. The company, which historically offered a dieting app, has been prescribing shots like Ozempic and Wegovy since May 2023. Noom also promised that its new program, called GLP-1Rx,

Read More »

Study finds that 42% of online pharmacies selling semaglutide are illegal

August 14, 2024 Nearly half of online pharmacies that sell semaglutide — the active ingredient in Ozempic and Wegovy — are doing so illegally, posing safety risks for consumers, according to a study published Aug. 2 in JAMA Network Open.  Of the 317 online pharmacies included in the study, researchers found 42.27% were operating illegally, meaning vendors were selling products without a license and without a prescription. Researchers also tested semaglutide samples that were ordered from six online pharmacies and found

Read More »

23 and me To Enter The Weight Loss Market

August 13, 2024 As reported by Fiercehealthcare.com today in an article… The genetic testing company 23andMe sees an opportunity to get in on the weight loss boom. The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with its fiscal first-quarter financial results. The service will enable members to be prescribed and receive brand-name or compounded semaglutide medications, the company said. “The addition

Read More »

Marketdata weight loss reports have been quoted by..

Scroll to Top